Francavilla Ruggiero, Lionetti Elena, Castellaneta Stefania Paola, Magistà Anna Maria, Boscarelli Giuseppe, Piscitelli Domenico, Amoruso Annacinzia, Di Leo Alfredo, Miniello Vito Leonardo, Francavilla Antonio, Cavallo Luciano, Ierardi Enzo
Department of Biomedicina dell'Età Evolutiva, Università degli Studi di Bari, Bari, Italy.
Gastroenterology. 2005 Nov;129(5):1414-9. doi: 10.1053/j.gastro.2005.09.007.
BACKGROUND & AIMS: The currently recommended first-line eradication treatment of Helicobacter pylori in children is usually successful in about 75%. Recently, in adults, a novel 10-day sequential treatment has achieved an eradication rate of 95%. The aim of the study was to assess the H pylori eradication rate of the sequential treatment regimen compared with conventional triple therapy in children.
Seventy-eight consecutive children with H pylori infection were randomized to receive either sequential treatment (omeprazole plus amoxicillin for 5 days, followed by omeprazole plus clarithromycin plus tinidazole for another 5 days) (n = 38; 15 boys [39.5%]; median age, 11.0 years [range, 3.3-16 years]) or triple therapy (omeprazole, amoxicillin, and metronidazole) for 1 week (n = 37; 15 boys [40.5%]; median age, 9.9 years [range, 4.3-16 years]). H pylori infection was based on 2 out of 3 positive tests results: 13C-urea breath test, rapid urease test, and histologic analysis. Eradication was assessed by 13C-urea breath test 8 weeks after therapy.
Seventy-four patients completed the study. H pylori eradication was achieved in 36 children receiving sequential treatment (97.3%; 95% confidence interval, 86.2-99.5) and 28 children receiving triple therapy (75.7%; 95% confidence interval, 59.8-86.7) (P < .02). Compliance with therapy was good (>95%) in all.
Our study shows, for the first time in children, that 10-day sequential treatment achieves a higher eradication rate than standard triple therapy, which is consistent with the results of adult studies.
目前推荐的儿童幽门螺杆菌一线根除治疗方案成功率通常约为75%。最近,在成人中,一种新型的10天序贯疗法根除率达到了95%。本研究的目的是评估序贯治疗方案与传统三联疗法相比在儿童幽门螺杆菌根除率方面的情况。
78例连续的幽门螺杆菌感染儿童被随机分为接受序贯治疗组(奥美拉唑加阿莫西林治疗5天,随后奥美拉唑加克拉霉素加替硝唑再治疗5天)(n = 38;15名男孩[39.5%];中位年龄11.0岁[范围3.3 - 16岁])或三联疗法组(奥美拉唑、阿莫西林和甲硝唑)治疗1周(n = 37;15名男孩[40.5%];中位年龄9.9岁[范围4.3 - 16岁])。幽门螺杆菌感染基于三项检测结果中的两项阳性:13C - 尿素呼气试验、快速尿素酶试验和组织学分析。治疗8周后通过13C - 尿素呼气试验评估根除情况。
74例患者完成了研究。接受序贯治疗的36例儿童实现了幽门螺杆菌根除(97.3%;95%置信区间,86.2 - 99.5),接受三联疗法的28例儿童实现了根除(75.7%;95%置信区间,59.8 - 86.7)(P <.02)。所有患者的治疗依从性均良好(>95%)。
我们的研究首次表明,在儿童中,10天序贯治疗的根除率高于标准三联疗法,这与成人研究结果一致。